Abstract
In December 2019, an outbreak of novel coronavirus threatened the health of mankind. There is no clinically proven vaccine apart from few antivirals treatments claiming efficacy. Although, corticosteroids have been widely used during outbreaks of severe acute respiratory syndrome and Middle East respiratory syndrome, there was significant controversy regarding their efficacy in treating coronavirus – 19. In infected Coronavirus disease- 2019 (COVID-19) patients, there is massive cytokine release called as ‘cytokine storm’ hyper inflammation and immune suppression with reduce helper CD4 cell response. Corticosteroids have a good inhibitory effect on inflammatory mediators and are often used as an additional treatment choice for viral pneumonia. The use of corticosteroids has been largely discouraged because of their immunosuppression effect & fear of worsening of viral propagation. Interest in corticosteroid therapy in COVID-19 has been studied after the results from Randomized Evaluation of COVID-19 therapy (RECOVERY) Trial. However, the World Health Organization has not recommended corticosteroid in the treatment of COVID-19. Many controversies have emerged about the use of corticosteroid in COVID 19.This review summarises the pathophysiology, role of corticosteroid in management, controversies about use of corticosteroid in COVID 19 disease. Various studies & literature review suggests that patients with severe conditions were more likely to require corticosteroids in treatment protocol. Corticosteroids should be used with caution in the treatment of COVID-19 patients & more multicentre clinical trials are further needed to support their use in management of covid-19.
References
- K. Singh et al,Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective, Diabetes & Metabolic Syndrome: Clinical Research& Reviews 14 (2020) 971e978
- Veronese et al., Corticosteroids in COVID-19 Pneumonia, Frontiers in Medicine | www.frontiersin.org 3 April 2020 | Volume 7 | Article 170
- Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006; 66:193‑292.
- Huang C, Wang Y , Li X , Ren L , Zhao J , Hu Y , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England)2020 Feb 15; 395 (10223):497–506
- Zunyou Wu, MD, PhD, Characteristics of and Important Lessons From the Coronavirus disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA April 7, 2020 Volume 323, Number 13
- Siddiqu HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical Therapeutic Staging Proposal. Journal of Heart and Lung Transplantation. doi: 10.1016/j.healun.2020.03.012
- Scott J Bergman et al, Drugs & Diseases> Infectious Diseases, Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies, Aug 10, 2020
- FDA NEWS RELEASE, Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment, May 01, 2020
- https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
- James M. Sanders et al, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review, JAMA. 2020;323(18):1824-1836
- Ashifa Trivedi et al,, Investigational treatments for COVID-19,The Pharmaceutical Journal23 JUN 2020
- https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
- Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, Zhang J, Qu JM, Cao B. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):183–184.
- K. Singh et al,Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective, Diabetes & Metabolic Syndrome: Clinical Research& Reviews 14 (2020) 971e978
- Víctor J. Costela-Ruiz, et al., Cytokine and Growth Factor Reviews, https://doi.org/10.1016/j.cytogfr.2020.06.001
- K. Singh et al, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective, Diabetes& Metabolic Syndrome: Clinical Research& Reviews 14 (2020) 971e978
- Yang, J. Liu and Y. Zhou et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis Journal of Infection 81 (2020) e13–e20
- https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients
- Iba et al, Coagulopathy of Coronavirus Disease 2019, Critical Care Medicine,2020
- Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J 2020; in press
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; published online Feb 7
- https://doi.org/10.1016/ S0140-6736 (20) 30361-5. Last accessed on 10th Aug 20.
- Zhenwei Yang et al, The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis, JID: YJINF [m5G;April 16, 2020;20:59)
Corresponding Author
Shweta Thadeshwar
DY Patil School of Medicine, Navi Mumbai
DOI: https://dx.doi.org/10.18535/jmscr/v8i12.48
